Thu, Aug 28, 2014, 3:44 AM EDT - U.S. Markets open in 5 hrs 46 mins

Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

blank2thisone 65 posts  |  Last Activity: 20 hours ago Member since: Jul 18, 2010
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • blank2thisone blank2thisone Jun 18, 2014 9:29 AM Flag

    Now we know why!

    Sentiment: Strong Buy

  • blank2thisone blank2thisone Jun 17, 2014 4:26 PM Flag

    Point is,....INSM signed this deal after they let Gupta go! Management is confident about outcome FDA. Yep, without Gupta!

    Sentiment: Strong Buy

  • Therapure will be responsible for the construction of a custom manufacturing suite for scale-up, commercial aseptic formulation and fill/finish manufacturing of Insmed’s ARIKAYCE at the Therapure facility in Mississauga, Ontario. Innovative technologies, such as the proprietary liposomal encapsulation process utilized in ARIKAYCE, are complementary to Therapure’s capabilities in the cGMP manufacturing of complex therapeutics.
    Mr. Nick Green, Therapure’s President and Chief Executive Officer, said: “We are delighted to partner with Insmed to assist with the advancement of this innovative technology for serious and life-threatening pulmonary diseases. Therapure prides itself on its development, clinical and commercial cGMP manufacturing expertise providing solutions for biologic therapeutics and innovative drug delivery technologies, which make a difference in patients’ lives.”
    “Insmed looks forward to working with Therapure for the commercial supply of our key drug candidate ARIKAYCE. Therapure’s proven cGMP manufacturing capabilities and expertise with aseptic formulation will support the planned global commercial launch of ARIKAYCE,” said Dr. Peter Clarke, Insmed’s Vice President of Technical Operations.

    Sentiment: Strong Buy

  • Status Update! On Tuesday, June 3, 2014, status on the RIKACIA trademark changed to FIRST EXTENSION - GRANTED.
    On Friday, June 28, 2013, a U.S. federal trademark registration was filed for RIKACIA by Insmed, Inc., Monmouth Junction, NJ 08852. The USPTO has given the RIKACIA trademark serial number of 85972462. The current federal status of this trademark filing is FIRST EXTENSION - GRANTED. The correspondent listed for RIKACIA is PETER J. WILLSEY of COOLEY LLP, 1299 PENNSYLVANIA AVE NW STE 700, WASHINGTON, DC 20004-2431 . The RIKACIA trademark is filed in the category of Pharmaceutical Products . The description provided to the USPTO for RIKACIA is Pharmaceutical preparations for the treatment of lung infections and pulmonary diseases.
    ====================================================================================

    Status Update! On Tuesday, May 20, 2014, status on the LONSPIRA trademark changed to THIRD EXTENSION - GRANTED.
    On Friday, April 20, 2012, a U.S. federal trademark registration was filed for LONSPIRA by INSMED INCORPORATED, Monmouth Junction, NJ 08852. The USPTO has given the LONSPIRA trademark serial number of 85604091. The current federal status of this trademark filing is THIRD EXTENSION - GRANTED. The correspondent listed for LONSPIRA is Peter J. Willsey of COOLEY LLP, 1299 Pennsylvania Avenue, NW, Suite 700, WASHINGTON DC 20004 . The LONSPIRA trademark is filed in the category of Pharmaceutical Products . The description provided to the USPTO for LONSPIRA is pharmaceutical preparations for the treatment of respiratory diseases and disorders.
    ====================================================================================

    Status Update! On Tuesday, May 20, 2014, status on the VONCERA trademark changed to THIRD EXTENSION - GRANTED.
    On Friday, April 20, 2012, a U.S. federal trademark registration was filed for VONCERA by INSMED INCORPORATED, Monmouth Junction, NJ 08852. The USPTO has given the VONCERA trademark serial number of 85604083. The current federal status of this trademark filing is THIRD EXTENSION - GRANTED. The correspondent listed for VONCERA is Peter J. Willsey of COOLEY LLP, 1299 Pennsylvania Avenue, NW, Suite 700, WASHINGTON DC 20004 . The VONCERA trademark is filed in the category of Pharmaceutical Products . The description provided to the USPTO for VONCERA is pharmaceutical preparations for the treatment of respiratory diseases and disorders.

    Sentiment: Strong Buy

  • blank2thisone blank2thisone Jun 16, 2014 3:02 PM Flag

    Yep...They are indeed deleted..I'll repost right away!

    Sentiment: Strong Buy

INSM
13.94-0.10(-0.71%)Aug 27 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
TubeMogul, Inc.
NasdaqGSWed, Aug 27, 2014 4:00 PM EDT
Burger King Worldwide, Inc.
NYSEWed, Aug 27, 2014 4:00 PM EDT